Education
About Us
Working with TipRanks
Follow Us
ImmunoPrecise Antibodies (IPA)
NASDAQ:IPA
IPA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.27 - $3.25
Previous CloseN/A
Volume74.57K
Average Volume (3M)1.73M
Market Cap
$126.92M
Enterprise Value$22.20M
Total Cash (Recent Filing)$12.91M
Total Debt (Recent Filing)$12.93M
Price to Earnings (P/E)―
Beta1.26
Next Earnings
Sep 11, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding46,154,118
10 Day Avg. Volume2,389,843
30 Day Avg. Volume1,731,538
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.17
Enterprise Value/Revenue0.92
Enterprise Value/Gross Profit1.82
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$3.67Price Target Upside38.49% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Bulls Say, Bears Say
Bulls Say
Facility ExpansionThe expansion of the Canadian facility, with an 83% increase in quarterly orders and a 93% increase in orders from new clients, supports future growth despite the Dutch divestiture.
Financial PerformanceImmunoPrecise Antibodies (IPA) reported positive financial results for their 4Q25, including revenues of CDN$7.0 million, up 8% year-over-year, with a reduced net loss of $2.2 million.
R&D AchievementsIPA has been very busy on the R&D front, highlighted by several recent breakthroughs achieved by the Company’s LENSai platform.
Bears Say
Geographic Footprint ReductionReducing the company's geographic footprint through divestment allows for better focus on the long-term strategy to grow the AI business.
Risk FactorsRisks associated with the company's future include commercial, execution, legal, competition, and intellectual property challenges.
ImmunoPrecise Antibodies News
IPA FAQ
What was ImmunoPrecise Antibodies’s price range in the past 12 months?
ImmunoPrecise Antibodies lowest stock price was $0.27 and its highest was $3.25 in the past 12 months.
What is ImmunoPrecise Antibodies’s market cap?
ImmunoPrecise Antibodies’s market cap is $126.92M.
When is ImmunoPrecise Antibodies’s upcoming earnings report date?
ImmunoPrecise Antibodies’s upcoming earnings report date is Sep 11, 2025 which is in 14 days.
How were ImmunoPrecise Antibodies’s earnings last quarter?
ImmunoPrecise Antibodies released its earnings results on Jul 29, 2025. The company reported -$0.036 earnings per share for the quarter, the consensus estimate of -$0.036 by $0.
Is ImmunoPrecise Antibodies overvalued?
According to Wall Street analysts ImmunoPrecise Antibodies’s price is currently Undervalued.
Does ImmunoPrecise Antibodies pay dividends?
ImmunoPrecise Antibodies does not currently pay dividends.
What is ImmunoPrecise Antibodies’s EPS estimate?
ImmunoPrecise Antibodies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ImmunoPrecise Antibodies have?
ImmunoPrecise Antibodies has 46,154,118 shares outstanding.
What happened to ImmunoPrecise Antibodies’s price movement after its last earnings report?
ImmunoPrecise Antibodies reported an EPS of -$0.036 in its last earnings report, expectations of -$0.036. Following the earnings report the stock price went down -14.851%.
Which hedge fund is a major shareholder of ImmunoPrecise Antibodies?
Currently, no hedge funds are holding shares in IPA
ImmunoPrecise Antibodies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.67 (38.49% Upside)
$3.67 (38.49% Upside)
Crowd Wisdom
Very Positive
Last 7 Days ▲ 4.2%
Last 30 Days ▲ 17.4%
Last 30 Days ▲ 17.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
246.78%
12-Months-Change
Fundamentals
Return on Equity
-102.69%
Trailing 12-Months
Asset Growth
-26.32%
Trailing 12-Months
Company Description
ImmunoPrecise Antibodies
ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and provision of related services in the United States, Canada, Europe, Australia, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its contract research organization services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation. The company has research collaboration agreements with Pierre Fabre S.A for antibody discovery; and Elektrofi, Inc. to explore a high-concentration formulation of COVID-19 antibody cocktail, PolyTope TATX-03. ImmunoPrecise Antibodies Ltd. was incorporated in 1983 and is based in Victoria, Canada.
IPA Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted strong performance in the fourth quarter with record revenues, significant margin improvements, and strategic partnerships driving growth in key segments, particularly BioStrand. The company's Canadian business also showed impressive growth. However, the overall fiscal year revenue growth was modest, and the divestiture of the Dutch subsidiary is taking longer than initially expected. Despite these challenges, the overall sentiment remains positive due to the company's achievements and strategic focus.View all IPA earnings summariesIPA Stock 12 Month Forecast
Average Price Target
$3.67
▲(38.49% Upside)
Technical Analysis
Lisata Therapeutics
―
Ovid Therapeutics
―
Passage Bio
―
Cardio Diagnostics Holdings
―
Jupiter Neurosciences, Inc.
―
Ownership Overview
5.04% Insiders
0.02% Mutual Funds
6.37% Other Institutional Investors
88.59% Public Companies and
Individual Investors